A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone.

Trial Profile

A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Fenofibrate (Primary) ; Pravastatin (Primary) ; Simvastatin
  • Indications Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; Fournier Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2010 Actual number of patients added to 423 as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Planned patient numbers amended from 400 to 423 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top